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Abstract
In colorectal cancer insulin-like growth factor II (IGF-II) is frequently overexpressed. To evaluate,
whether IGF-II affects different stages of tumorigenesis, we induced neoplastic alterations in the
colon of wild-type and IGF-II transgenic mice using 1,2-dimethylhydrazine (DMH). Aberrant crypt
foci (ACF) served as markers of early lesions in the colonic mucosa, whereas adenomas and
carcinomas characterized the endpoints of tumor development. DMH-treatment led initially to
significantly more ACF in IGF-II transgenic than in wild-type mice. This increase in ACF was
especially prominent for those consisting of ≥three aberrant crypts (AC). Nevertheless, adenomas
and adenocarcinomas of the colon, present after 34 weeks in both genetic groups, were not found
at different frequency. Tumor volumes, however, were significantly higher in IGF-II transgenic mice
and correlated with serum IGF-II levels. Immunohistochemical staining for markers of proliferation
and apoptosis revealed increased cell proliferation rates in tumors of IGF-II transgenic mice without
significant affection of apoptosis. Increased proliferation was accompanied by elevated localization
of β-catenin in the cytosol and cell nuclei and reduced appearance at the inner plasma membrane.
In conclusion, we provide evidence that IGF-II, via activation of the β-catenin signaling cascade,
promotes growth of ACF and tumors without affecting tumor numbers.
Background
Aberrant crypt foci (ACF) are generally accepted to repre-
sent precursor lesions in stepwise colon cancer develop-
ment and emerge in the colon of rodents after treatment
with 1,2-dimethylhydrazine (DMH) [1,2]. ACF were also
found in humans who underwent surgery for colorectal
cancer [3]. ACF in an unembedded colon are character-
ized by increased size of the crypts, a thickened layer of
epithelial cells, an increased pericryptal space and an
irregular lumen [4,5]. Although in carcinogen-treated
rodents and patients with sporadic colorectal cancer
(CRC) only a small fraction of ACF progresses to a tumor,
there is a clear association between the development of
ACF and tumor formation, at least in the colon of rodents
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[6]. These data are further supported by the observation
that patients with colon cancer resident in regions with
high incidence rates of colorectal cancer have higher den-
sity of ACF in the colonic mucosa than patients from low
incidence regions. Moreover, patients with familial ade-
nomatous polyposis (FAP) ACF showed definite dysplasia
in 75–100% of the cases [6], whereas in patients who suf-
fer from sporadic CRC a large fraction of ACF were found
to be hyperplastic with a lower potential for malignant
progression [2]. In humans most sporadic colorectal
tumors are located in the middle part of the colon and in
the rectum [7]. This specific location of tumors is also
found after DMH-treatment of rodents [8]. DMH has
been shown to cause DNA damage by alkylating DNA,
resulting in the pro-mutagenic lesion O6-methylguanine
(O6-MeG) [9], that is known to induce GC→AT transi-
tions [10]. Such mutations are typically found in various
genes linked to colon cancer, like β-catenin [11] or K-ras
[12].
In humans IGF-II was suggested to play a role in develop-
ment of CRC, as substantiated by findings showing that
IGF-II is overexpressed in about 44% of all colorectal
tumors due to a loss of imprinting (LOI) in the IGF2 gene
[13]. The LOI characterizes a cancer-prone state since it is
specifically found in the transformed colonic mucosa of
most patients with CRC, but occurs rarely in individuals
without cancer [13].
On a molecular basis, the importance of IGF-II for stimu-
lation of growth was shown in several colon cancer cell
lines [14,15]. Moreover, there is evidence, that IGF-II
interferes with wnt-signaling by inducing the redistribu-
tion of β-catenin from the plasma membrane to the
nucleus, as was shown in rat bladder carcinoma cells [16].
Although it has not been demonstrated so far that IGF-II
affects β-catenin localization also in CRC, the develop-
ment of CRC is almost invariably associated with nuclear
accumulation of β-catenin [17], leading to complexes
with the transcriptional repressors of the TCF/LEF family
and the activation of target genes encoding growth pro-
moting factors [18].
Besides the observation that IGF-II exhibits strong
mitogenic potential, prevention of apoptosis could be
another mechanism through which IGF-II might enforce
tumor development [19]. Interference with the wnt-sign-
aling pathway could play a role in this regard in so far as
activation of this pathway was demonstrated to reduce the
protein levels of caspase-3, 7 and 9 [20].
Finally, IGF-II might enhance the spread of CRC by the
induction of lymphangiogenesis, as this process contrib-
utes to the infiltration of metastases in lymph nodes [21]
and has been shown to be increased in vivo in the cornea
of mice through IGF-II [22].
In the present study, we used IGF-II transgenic mice in
order to investigate the influence of IGF-II on the develop-
ment of ACF, adenomas and carcinomas in the colon that
were induced by the chemical carcinogen DMH. Immuno-
histochemical staining of 5-bromo-2'-deoxyuridine
(BrdU) and cleaved caspase-3 served to assess the effects
of IGF-II on proliferation and apoptosis rates in vivo,
respectively. Moreover, staining of β-catenin in the tumors
served to indicate an activation of the wnt-signaling cas-
cade. Quantitative detection of LYVE-1, a marker for lym-
phangiogenesis, was used to reveal effects of IGF-II on
metastasis. In addition to IGF-II, serum levels of IGF-I and
IGF-binding protein-2 (IGFBP-2) were assessed in order
to exclude that decreases in IGF-I and increases in IGFBP-
2 antagonize the IGF-II effects in a compensatory manner
[23].
Materials and methods
Identification of PEPCK-IGF-II transgenic animals and 
carcinogen treatment
Female NMRI mice, overexpressing human IGF-II under
the control of the rat phosphoenolpyruvate carboxykinase
(PEPCK) promoter in several tissues including colon [24]
and their non-transgenic female NMRI littermates were
used in this study. To distinguish transgenic mice and
their non-transgenic littermates animals were genotyped
by PCR using the following primers for IGF-II: 5' ATG
GGA ATC CCA ATG GGG AAG 3' and 5' CTT GCC CAC
GGG GTA TCT GGG 3'. These primers generate a 336 bp
product from the transgenic human IGF2  DNA [25].
Genomic DNA was prepared from mouse-tail biopsies.
Samples were digested with Kawasaki buffer and Protein-
aseK. PCR products were analyzed by agarose gel electro-
phoresis with ethidium bromide under UV light. The
PCR-analysis revealed that 60 of the 124 animals were
transgenic.
To investigate the impact of IGF-II on different stages of
colon cancer development, IGF-II transgenic and non-
transgenic mice were allocated into two groups, respec-
tively, treated either with DMH or not (controls). DMH
was applied by intraperitoneal (i.p.) injections of 40 mg/
kg body weight DMH (Sigma, Deisenhofen, Germany) as
aqueous solution [0.9% NaCl, 1 mM EDTA] once a week
for 6 weeks from the age of 4 weeks on (group1: IGF-II-
transgenic, early stage n = 24, late stage n = 7; and group3:
wild-type, early stage n = 25, late stage n = 10). Transgenic
and non-transgenic control animals received saline [0.9%
NaCl, 1 mM EDTA] instead of DMH (group2: IGF-II trans-
genic, early stage n = 22, late stage n = 7, and group4: wild-
type, early stage n = 24, late stage n = 5). All mice had free
access to tap water and a standard diet (V1534; Ssniff,Journal of Carcinogenesis 2006, 5:24 http://www.carcinogenesis.com/content/5/1/24
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Soest, Germany), and were weighed weekly and moni-
tored closely for signs of illness. None of the groups
showed significant differences in weight gain. All experi-
ments were carried out according to the German Animal
Protection Law (2112531-37/00).
RT-PCR
Tissue samples from the colons of PEPCK-IGF-II trans-
genic mice and non-transgenic littermates were immedi-
ately frozen on dry ice and stored at -80°C. Tissues were
homogenized in Tri-Pure™ isolation reagent (Roche Diag-
nostics, Mannheim, Germany) using an ULTRA-TURRAX
System T25 (ART, Mühlheim, Germany), and total RNA
was prepared according to the manufacturer's instruc-
tions. 2.5 μg RNA were reversely transcribed into cDNA
for 60 min at 37°C using 1× first strand buffer (Tris/HCl,
pH8.3, KCl, MgCl2) (Invitrogen, Karlsruhe, Germany), 10
mM DTT (Invitrogen), dNTPs (1 mM each), 25 ng/μl
Oligo(dT) primer and 20 U M-MLV reverse transcriptase
(Invitrogen). The reaction was terminated for 5 min at
95°C. The amplification of human and murine IGF-II
sequences was performed with species-specific primers as
described [25]. Both primer-pairs yielded an amplifica-
tion product of 499 bp [25]. The integrity of cDNA was
confirmed by β-actin specific primers 5' GGC ATC GTG
ATG GAC TCC G 3' (β-actin: forward), 5' GTC GGA AGG
TGG ACA GCG A 3' (β-actin: reverse). PCR analyses were
carried out in 20-μl reactions containing 2 μl cDNA, 0.5 U
Taq polymerase (Qiagen), 50 μM dNTPs, 1× PCR-buffer
[Tris-HCl, KCl, (NH4)2SO4, 1.5 mM MgCl2, pH 8.7 at
20°C], 1× Q-Solution (Qiagen) and 0.1 μM of both sense
and antisense primers. β-actin reactions contained addi-
tional 1.5 mM MgCl2 (Qiagen). The amplification was
performed as follows: samples were heated at 94°C for 4
min followed by 40 cycles of 94°C for 1 min, 60°C for 1
min and 72°C for 2 min. After a final extension at 72°C
for 10 min samples were analyzed by agarose gel electro-
phoresis.
Determination of serum IGF-II, IGF-I and IGFBP-2
Blood samples were taken by orbital puncture from mice
under ether anesthesia before cervical dislocation. Sam-
ples were stored at 4°C for 30 min and centrifuged twice
for 10 min at 10000 × g at 4°C to obtain serum. Serum
samples were stored at -20°C until further analysis. Serum
concentrations of IGF-II, IGF-I and IGFBP-2 were deter-
mined by radioimmunoassays (RIAs), which were stand-
ardized in the hormone laboratory of the Children's
Hospital, University of Tübingen as previously described
[24].
Aberrant colonic crypt analysis and evaluation of tumor 
development
Animals were killed by cervical dislocation 5 (early stage)
or 34 (late stage) weeks after the last carcinogen or saline
injection, respectively. The colons were removed and
rinsed with ice-cold Tris buffer (pH7.4). The colons were
dissected along the longitudinal median axis, then placed
on microscopic slides with the mucosal side up and fixed
flat between filter paper and the microscopic slide in 10%
neutral buffered formalin for three hours. The colonic
crypts were stained with 2 g/l of methylene blue in PBS for
10–15 min. The number of ACF and the aberrant crypt
multiplicity were determined by light microscopy at 25-
fold magnification. All colons were scored by one
observer. Several groups were rescored blindly. A few
colons were repeated by a second observer and an inter-
observer variation of less than 3% was observed. At the
late stage, visible tumors were numbered and their loca-
tion was recorded. The colon was fixed and stained for
ACF and microadenomas as described before. Thereafter,
each specimen was examined under a light microscope.
Tumors were cut out and fixed in 10% neutral buffered
formalin for further 20 hours. All tumors in the colon
were routinely processed and embedded in paraffin.
Before embedding, the tumors were measured in three
perpendicular directions using a slide calliper. The gross
tumor volume was calculated using the equation V = 4/3
π r3, where r was the average tumor radius. The tumors
were cut in the middle and embedded with the section flat
down. Serial tissue sections (3–4 μm) were made and
mounted on glass slides.
Histopathological grading of tumors
Hematoxylin and eosin (H&E)-stained serial sections
were used for histological grading. The grading of tumors
was based on pleomorphic morphology and invasive
growth of the tumor cells, penetrating the lamina muscu-
laris mucosae. The sections were analyzed by light micro-
scopy at 400 times magnification.
Immunohistochemistry (IHC)
For determination of the proliferative activity in the neo-
plasms, two hours (h) before sacrificing, mice were
injected i.p. with 30 mg/kg body weight BrdU. BrdU is a
pyrimidine analog which is incorporated by DNA-synthe-
sizing nuclei and used for the identification of S-phase
cells and was found to give the most accurate reflection of
the proliferation rate [26]. Tissue samples were obtained
and processed as described above. Paraffin-embedded
serial tumor sections were routinely dewaxed, rehydrated
and digested for 2 min with 0.01% trypsin before endog-
enous peroxidase was quenched with 3% H2O2 in Tris-
HCl buffer pH7.8. After blocking non-specific protein-
protein interactions with 1% BSA in Tris-HCl buffer for 60
min at room temperature, the slides were incubated with
mouse-anti-BrdU monoclonal antibody (Sigma) diluted
1:10 in blocking buffer for 90 min at room temperature.
Subsequently, secondary peroxidase-conjugated antibody
directed to IgG from mouse (Sigma) was diluted 1:10 inJournal of Carcinogenesis 2006, 5:24 http://www.carcinogenesis.com/content/5/1/24
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Tris-HCl buffer containing 1% BSA and incubated 60 min
at room temperature. Slides were thoroughly washed with
Tris-HCl buffer between the incubation steps. All sections
were counterstained with hematoxylin and mounted in
entellan (Merck). Brown nuclei indicated cells in S-phase.
For determination of apoptosis in the colon tumors, IHC
for cleaved caspase-3 was performed on formalin-fixed
and paraffin-embedded tissue samples. Sections were
dewaxed in xylene, endogenous peroxidase was blocked
with 0.5% H2O2 in methanol and epitope retrieval was
performed by microwaving for 33 min in citrate buffer
(pH6.0) in a microwave pressure cooker at 750 W. The
rabbit polyclonal cleaved caspase-3 (Asp175) antibody
(Cell Signaling, Frankfurt, Germany) was diluted 1:200 in
blocking buffer (5% goat serum in TBS, pH7.6) and incu-
bated overnight. Biotinylated anti-rabbit IgG (dilution
1:200) (Vector Laboratories, Wertheim, Germany) served
as secondary antibody. The Avidin Biotin Complex
Vectastain Elite Peroxidase-based system (Vector Labora-
tories) with diaminobenzidine as the substrate (Sigma)
served for visualization of cleaved caspase-3. Sections
were counterstained as described for BrdU staining.
Brown nuclei indicated cells that underwent apoptosis.
To demonstrate the presence and localization of β-catenin
in the colorectal tumors, slides were pretreated as
described for cleaved caspase-3 staining and incubated
with a β-catenin-specific antibody (clone14, BD Pharmin-
gen, Heidelberg, Germany) with strong reactivity against
mouse β-catenin in a dilution of 1:10000. Biotinylated
anti-mouse IgG (dilution 1:200) (Vector Laboratories)
served as secondary antibody. Visualization of β-catenin
and counterstaining was done as described for cleaved
caspase-3 staining. Positive staining for β-catenin was
detected in the nuclei, the cytoplasm and the cell mem-
branes.
For visualization of lymphatic vessels in the tumors, treat-
ment of slides and incubation steps were performed as
described for cleaved caspase-3. For IHC rabbit polyclonal
LYVE-1 antibody (DCS, Hamburg, Germany) was used in
a dilution of 1:50. Brown cell membranes indicated posi-
tive staining.
Negative controls for all stainings were done by omitting
primary antibodies. No positive staining was obtained in
the case of cleaved caspase-3 and LYVE-1 staining. There
was a slight signal in the negative control of β-catenin
staining with the biotinylated anti mouse IgG of the tubu-
lar lumen and of immune cells in the stroma, but not of
epithelial cells.
Evaluation of BrdU and activated caspase-3 labeling
Tumors were scanned microscopically (×50 and ×100) to
identify areas of most intense (hot spots) nuclear staining.
The percentage of immunoreactive tumor cell nuclei of
either BrdU or activated caspase-3 positive cells (prolifer-
ative rate, apoptosis labelling index) were calculated by
counting 900–1500 epithelial cells at magnification
(×200) within selected areas of at least five representative
microscopic fields. Images were captured with the micro-
scope coupled to a camera and digitalized on a computer.
All brown nuclei and non-stained nuclei (blue) were
marked before the percentage of positive staining was cal-
culated. All tumors were scored by two observers, with
one person blind to the different groups. Scored regions
were chosen by the individual observer. The coefficient of
variation between the two observers was in general lower
than 5%.
Evaluation of β-catenin localization
Staining intensity of the cell membrane was compared
with non-tumorous epithelial cells that served as an inter-
nal positive control, and was graded into three categories:
loss, reduced and preserved. Loss = disappearance of
membrane staining in more than 80% of the tumor cells.
The reduced type was split into cases with weak (loss in
about 10–20%), moderate (loss in about 20–50%), and
strong (loss in more than 50% of the cells) reduction of
membrane staining. In the preserved type, tumor cells
were found to be homogeneously positive for membrane
staining. The staining of the epithelial tumor cells was
evaluated under light microscopy by one observer and
confirmed by a second one independently.
Nuclear staining of positive cells was defined as intense
brown color in the nucleus. The pattern of nuclear immu-
nohistochemical staining was evaluated under the light
microscope by one observer and confirmed by a second
one independently. The scored adenomas were classified
as follows: negative or scattered (no or very few scattered
positive cells without any clusters), focal positive cells
clustered in focal areas (+ = positive cells in some small
areas ~15–20%, ++ = positive cells in wide parts of the
tumor ~20–25%, +++ = positive cells in most of the tubu-
lar constructions ~25–30%), diffuse (positive cells distrib-
uted diffusely and found in the vast majority of tubular
constructions of the tumor >30%).
Immunohistochemical staining intensity of the cytoplasm
was evaluated by microscopic images of immunostained
sections and quantified based on optical density using an
image analysis system (Optimas Software, Media Cyber-
netics, Silver Spring). Cytoplasmic intensity of tumor tis-
sue (T) was analyzed by randomly processing at least 100
tumor epithelial cells in areas which were previously
scored under light microscope for loss of, stronglyJournal of Carcinogenesis 2006, 5:24 http://www.carcinogenesis.com/content/5/1/24
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reduced, weakly reduced, moderately reduced and pre-
served membrane staining, respectively, at ×400 magnifi-
cation in 4 different microscopic fields of each region. As
an internal control for each section, normal cytoplasmic
intensity (N) was measured in 100 normal epithelial cells
from the colon crypts. The definition of the percentage of
cytoplasmic intensity was as follows: (1-N/T) × 100.
Analysis of the lymphatic network
The overall lymphatic vessel density (number of lym-
phatic vessels per square millimeter) and lymphatic vessel
area (area of lymphatic vessels per square μm) were deter-
mined. The occurrence of lymphatic vessels in the tumor
tissue and in the stalk was assessed. The origin of the stalk
arises from the stroma of the normal colon and spreads
into the tumor, therefore this tissue builds a connection
between normal colon stroma and the reactive stroma of
the tumor. Image analysis was done using computer soft-
ware. In brief, images from the whole tumor tissue were
captured with the microscope coupled to a camera and
digitalized on the computer. Lymphatic vessels were
counted and the areas of vessels were automatically calcu-
lated by the software, after manually surrounding the ves-
sel.
Statistical analysis
Data were expressed as the mean ± SE, and were analyzed
using Graph Pad Prism Version 3.0 (Prism; Graph Pad,
San Diego, CA). Analysis of normally distributed data was
performed using Student's t-test. Non-parametric data
were analyzed using Mann-Whitney U-test. Differences
were considered as statistically significant at P < 0.05.
Results
Expression of human IGF-II in the colon of transgenic mice
The expression of human IGF-II mRNA in the colon was
analyzed by RT-PCR and could only be detected in
PEPCK-IGF-II transgenic mice. Treatment with DMH did
not induce the expression of endogenous IGF-II at the
mRNA-level, neither in transgenic animals nor in their
non-transgenic littermates with β-actin used as an expres-
sion control (data not shown).
Serum IGF-II, IGF-I, and IGFBP-2 levels
DMH-treatment did not influence the serum IGF-II con-
centrations neither in the transgenic mice nor in the non-
transgenic mice and neither at 11 weeks (15 weeks old
mice) nor at 40 weeks (44 weeks old mice) after the first
DMH application (Fig. 1A). IGF-II-levels in non-trans-
genic mice were significantly lower than in transgenic
mice at both time points measured (Fig. 1A). In the wild-
type mice there was a slight but significant increase of IGF-
II serum levels over time (19.52 ± 0.92 ng/ml versus 29.8
± 1.9 ng/ml in DMH-treated, 18.72 ± 0.68 ng/ml versus
28.4 ± 0.87 ng/ml in non-treated animals at the age of 15
and 44 weeks, respectively) that was not observed in IGF-
II transgenic animals (Fig. 1A).
Serum IGF-I concentrations were not affected by DMH-
treatment or genotype nor did they change over time (data
not shown).
DMH-treatment also had no influence on serum IGFBP-2
levels in both genotypes and at both time points meas-
ured (Fig. 1B). Although not as prominent as observed for
IGF-II levels, IGFBP-2 concentrations in the serum of 15
Effect of DMH-treatment and age on the serum level of IGF-II (A) and IGFBP-2 (B) in PEPCK-IGF-II transgenic (tg) and wild- type (wt) mice Figure 1
Effect of DMH-treatment and age on the serum level of IGF-II (A) and IGFBP-2 (B) in PEPCK-IGF-II transgenic (tg) and wild-
type (wt) mice. IGF-II and IGFBP-2 were measured 11 and 40 weeks after the first DMH-application or in untreated age-
matched controls by RIA. ●, ■ tg + DMH; ▲, ▼ tg without DMH; ❍,  wt + DMH; , Ќ wt without DMH.
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week old transgenic mice were significantly higher than in
the serum of wild-type mice (Fig. 1B) and correlated pos-
itively with IGF-II levels (P < 0.05, r2 = 0.18; data not
shown). At 44 weeks serum IGFBP-2 levels were signifi-
cantly increased in transgenic mice treated with DMH ver-
sus DMH-treated wild-type mice but no longer different
between both genotypes when untreated (Fig. 1B).
Development of ACF
Single aberrant crypts (AC) and clusters of AC, aberrant
crypt foci (ACF) consisting of multiple AC (Fig. 2A), were
found in IGF-II transgenic as well as in non-transgenic
mice after DMH-treatment, but not when treated with
vehicle only. The total number of ACF was significantly
higher (P < 0.001) in the colons of IGF-II transgenic mice
(47.66 ± 2.62 per 10 cm2) than in wild-type mice (26.68
± 2.48 per 10 cm2) at 11 weeks after the first DMH appli-
cation (Fig. 2B). This difference in ACF development was
no longer present after additional 29 weeks (IGF-II trans-
genic: 15.67 ± 3.12 per 10 cm2 versus wild-type: 15.56 ±
4.45 per 10 cm2) (Fig. 2B). In the late stage of carcinogen-
esis at 40 weeks after the first DMH application, especially
in the IGF-II transgenic mice the occurrence of the ACF
was found to be drastically reduced (P < 0.001) versus the
earlier stage (Fig. 2B). Since serum IGF-II levels in trans-
genic animals were still higher at this time point when
compared to wild-type mice, IGF-II seems not to affect
numbers of ACF at a later stage (Fig. 2B). In contrast, in
the earlier stage of carcinogenesis a clear correlation
between total numbers of ACF and serum IGF-II was
found (Fig. 2C). Although IGF-II increased all clusters of
ACF at five weeks post DMH-treatment, especially those
consisting of ≥ three AC were enhanced (Table 1). The
number of ACF with ≥ three AC remained constant over
time, whereas the reduction in total number of ACF in
both genotypes at a late stage was due to the reduced
number in ACF containing one to three AC (Table 1).
Tumor development
Following DMH-treatment, 4/7 (57%) PEPCK-IGF-II
transgenic mice and 4/10 (40%) non-transgenic litterma-
tes developed tumors within 34 weeks. The transgenic ani-
mals developed 12 tumors in total, whereas in wild-type
mice 8 tumors were found. The vast majority of the
tumors found in the colon of wild-type mice were located
in the distal colon (7/8) and only one tumor was located
in the mid-colon. In contrast, IGF-II transgenic mice bore
50% of tumors (6/12) in the mid-colon. In both geno-
types, no tumors were found in the proximal colon.
Importantly, the tumor incidence and the tumor number
per animal were not affected by IGF-II. However, an
increased tumor size was observed in IGF-II transgenic
mice (Fig. 3A) with a mean tumor volume (21.4 ± 5.7
mm3) 5.1-fold higher (P = 0.012) than in wild-type mice
(4.2 ± 1.0 mm3). The tumor volume was clearly positively
correlated with IGF-II serum levels (Fig. 3B).
Histopathological and histochemical analysis
All 20 tumors found in the colon of DMH-treated mice
were evaluated histologically. The histological analysis of
the tumors revealed that the DMH injected mice mainly
developed adenomas (non-transgenics: 5/8; IGF-II-trans-
genics: 11/12). Two of the colon tumors in wild-type mice
and one colon tumor of an IGF-II transgenic mouse were
classified as adenocarcinomas. One malignant lesion in
wild-type mice was classified as an adenosquamous carci-
noma, based on malignant squamous epithelial cells. The
classification of carcinoma was based on pleomorphism
and invasiveness into the lamina muscularis mucosae and
into blood vessels.
Proliferation and apoptotic indices of tumor epithelium
To assess whether IGF-II affects epithelial cell prolifera-
tion or apoptosis in the neoplasms of the colon, BrdU-
incorporation in S-phase cells and positive staining for
cleaved caspase-3 was visualized in all tumors. Examples
Table 1: Numbers of ACF with different crypt multiplicity in IGF-II transgenic (tg) and wild-type (wt) mice at different time points
number of ACF
AC/focus genotype early stage late stage P-value
1 AC tg 12.4 ± 1.0a 2.6 ± 1.2 P < 0.001
wt 8.7 ± 0.9 1.7 ± 0.7 P < 0.001
2 AC tg 17.4 ± 1.0a 6.0 ± 1.4 P < 0.001
wt 12.9 ± 1.4 6.0 ± 1.7 P < 0.01
3 AC tg 12.7 ± 1.0c 4.1 ± 0.8 P < 0.001
wt 5.9 ± 4.6 4.6 ± 1.4
4 AC tg 4.2 ± 0.7c 2.3 ± 0.6
wt 1.1 ± 0.2 0.9 ± 0.5
≥5 AC tg 1.5 ± 0.3a 1.9 ± 0.6
wt 0.7 ± 0.3 2.6 ± 1.1 P = 0.071
aP < 0.05,cP < 0.001 significance of differences between the two genetic groups. The P-value in the last row expresses the significance of difference 
between different time points within the same genotype.Journal of Carcinogenesis 2006, 5:24 http://www.carcinogenesis.com/content/5/1/24
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for the anti-BrdU staining in adenomas from transgenic
and non-transgenic mice are shown in Figure 4A and
examples of nuclear immunoreactivity versus cleaved cas-
pase-3 in apoptotic cells of adenomas from transgenic and
wild-type mice are given in Figure 4B.
The fraction of BrdU positive cells in adenomas of IGF-II
transgenic mice (24.86 ± 1.57%) was much higher than in
wild-type mice (16.84 ± 4.56%) (P < 0.05).
The relative presence of nuclei stained for cleaved caspase-
3 was generally very low in all tumors of both genotypes.
Wild-type mice showed more apoptotic epithelial cells
(1.69 ± 0.54%) in the adenomas than IGF-II transgenic
animals (0.94 ± 0.28%) without reaching statistical signif-
icance.
Distribution of β-catenin staining in adenomas
The results of cellular β-catenin localization in adenomas
of wild-type and IGF-II transgenic animals are shown in
Tables 2, 3 and 4 and examples of different patterns of dis-
tribution are shown in Figure 5.
In wild-type mice 60% of the adenomas exhibited a pre-
served (Fig. 5Ba,b, Table 2) or a weakly reduced (Fig. 5Bc,
Table 2) staining of the cell membrane, whereas only
ACF-development in IGF-II transgenic (tg) and non-transgenic (wt) mice Figure 2
ACF-development in IGF-II transgenic (tg) and non-transgenic (wt) mice. (A) Photographs of methylene blue-stained mucosa 
of colons from animals treated with vehicle (a) or with six i.p. injections of DMH (b, c, d). Photographs were made at the age 
of 15 or 44 weeks. Shown is an example of normal colon mucosa and examples of ACF with different numbers of AC (objec-
tive 5 × 0.5). (B) ACF in DMH-treated mice in the early (11 weeks after first DMH-treatment) and late (40 weeks after first 
DMH-treatment) stages of tumor development. (C) Correlation between serum IGF-II and number of ACF per mouse in 
DMH-treated PEPCK-IGF-II transgenic (●, ■) and wild-type mice (❍, ).
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22.2% of the adenomas from the IGF-II transgenic mice
revealed this type of staining (Table 2). Adenomas from
IGF-II transgenic animals also displayed a higher fraction
of moderately or strongly reduced membrane staining
(Fig. 5Bd, Table 2). The almost complete loss of mem-
brane staining was restricted to adenomas from IGF-II
transgenic mice (Fig. 5Be,f, Table 2).
The reduction of cell membrane staining in adenomas
from IGF-II transgenic mice was associated with an
increased staining of β-catenin in the cytoplasm, e.g. 89%
of the adenomas from IGF-II transgenic animals, but only
40% of the adenomas from wild-type mice showed a cyto-
plasmic staining intensity exceeding that of non-tumor-
ous tissue by more than 15% (Fig. 5Bd–f, Table 3). Weak
or low cytoplasmic staining was mainly found in the ade-
nomas of wild-type mice, whereas only one adenoma of
the IGF-II transgenic mice exhibited cytoplasmic staining
lower than 15% (Fig. 5Ba–c, Table 3). The mean fractions
of cytoplasmic staining intensity in adenomas from IGF-II
transgenic (25.52 ± 2.39%) and wild-type mice (11.83 ±
3.4%) adenomas were significantly different (P < 0.01).
Simultaneous to the cytoplasmic increase in β-catenin
staining nuclear staining intensities were found to be
enhanced in adenomas from IGF-II transgenic mice. Dif-
fuse presence of nuclear β-catenin staining was only
found in an adenoma of an IGF-II transgenic mouse but
not in adenomas of wild-type mice (Table 4), and was
accompanied by a complete loss of membrane-specific
staining (Fig. 5Bf). Focal nuclear staining was also found
at higher rates in adenomas from IGF-II transgenic ani-
mals (Fig. 5Bc–e, Table 4). Moreover, absence of nuclear
staining was found in 40% of adenomas from wild-type
mice, but only in 11% of adenomas from IGF-II trans-
genic mice (Fig. 5Ba,b, Table 4).
Lymphangiogenesis
Staining of lymphatic endothelial cells was clear and dis-
tinct, whereas endothelial cells in blood vessels were not
stained in both normal and tumorous colon (Fig. 6A).
Moreover, lymphatic endothelium was localized in con-
nective tissues such as submucosa and lamina propria
(Fig. 6A, left panel). In pedunculated adenomas the lym-
phatic endothelium pervaded the tumor tissue through
the stalk, which penetrated the tumor (Fig. 6Ba), and was
also found in the connective tissue in the middle (Fig.
6Bb) and marginal parts of the tumors (Fig. 6Bc). The LVD
(lymphatic vessel density) and the proportion area of
lymphatic vessels (mean area of endothelial vessels per
area tumor tissue) of endothelium in the tumors of both
genotypes were approximately 2.5 per mm2  and 1%,
respectively. Also the distribution of the lymphatic
endothelium within the tumors did not differ between the
two genotypes.
Discussion
IGF-II is suggested to play a role in the development and
progression of colorectal tumors [23,27]. On a molecular
basis, cell culture studies provided insights into the mode
of action by which IGF-II might influence processes,
which are relevant for carcinogenesis [14,15]. Moreover,
animal studies showed that IGF-II plays a role for cancer
development also in vivo [28,29]. Evidence for a crucial
role of IGF-II for colorectal cancer development in
humans stems from a report demonstrating overexpres-
sion of IGF-II in tumorous colonic tissue, as a conse-
quence of loss of imprinting in the IGF2 gene [13,30].
Effects of IGF-II on tumor volume Figure 3
Effects of IGF-II on tumor volume. (A) Tumors in the colon (arrows) of a wild-type (wt) (upper panel) and an IGF-II transgenic 
(tg) animal (lower panel). (B) Significant positive correlation between IGF-II-level in serum and the mean tumor volume.
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Effects of IGF-II overexpression on the development of
colorectal cancer have been investigated previously in the
ApcMin/+ mouse, containing a loss-of-function mutation in
the Apc gene [29]. This mutation is found in familial ade-
nomatous polyposis coli [31], but also during sporadic
colon cancer development in humans [32]. Although Apc-
Min/+ mice are used as a model for the investigation of
colorectal tumor development it has to be stressed that
ApcMin/+mice develop tumors predominantly in the small
intestine, questioning whether they really represent a
valid model for sporadic colon cancer development in
humans. To circumvent these obvious obstacles, we initi-
ated colorectal cancer using the chemical carcinogen
DMH, that induces tumors specifically in the descending
colon of rodents [7,8]. The relevance of the present model
is further shown by the histopathological findings in
DMH-treated mice, that were similar to those observed in
human sporadic colon tumors [33]. Using IGF-II trans-
genic mice we tested how IGF-II affects early and late
stages of chemically induced colorectal cancer in vivo.
DMH-treatment does not affect IGF-II expression
IGF-II transgenic mice displayed almost three-fold higher
serum IGF-II levels than non-transgenic mice at 11 weeks
after the first DMH application, and more than two-fold
higher serum IGF-II levels at 34 weeks after complete
DMH initiation. Serum IGF-II levels were independent of
DMH-application. However, since the liver carcinogen
diethylnitrosamine has been shown to induce re-expres-
sion of endogenous IGF-II in the liver of mice in a dose-
dependent fashion [25], we tested in addition whether
DMH influences the IGF2 mRNA expression in the colon.
DMH treatment did not induce the expression of IGF2 in
the colon of mice, indicating that the effect of IGF-II on
preneoplastic alterations (ACF) in the colon was due to
the IGF-II transgene.
IGF-II increases the number of ACF and the tumor size but 
not the tumor incidence
Non-treated IGF-II transgenic mice did not develop ACF,
whereas IGF-II transgenic mice treated with DMH exhib-
ited significantly more ACF in an early phase of tumor
development than the non-transgenic DMH-treated mice.
These data demonstrate that the development of ACF
requires an initiating stimulus. Moreover, it shows that
IGF-II alone is not able to initiate tumor development but
it increases precancerous lesions once initiation has been
triggered. Interestingly, at an early stage of tumor develop-
ment IGF-II transgenic mice displayed predominantly
more ACF containing ≥three AC. In the later stages in both
genotypes, but more prominent in IGF-II transgenic mice,
the ACF with less than three AC declined. Since the
number of tumors did not differ significantly between
transgenic and non-transgenic animals it is suggested that
the number of ACF present at a later stage of carcinogene-
sis is more important for tumor development than the
number at an early stage or the number of AC within an
ACF. In this regard, IGF-II seems to provide a growth-
Nuclear immunohistochemical staining of proliferation and  apoptosis markers in adenomas from IGF-II transgenic (tg) or  wild-type (wt) mice Figure 4
Nuclear immunohistochemical staining of proliferation and 
apoptosis markers in adenomas from IGF-II transgenic (tg) or 
wild-type (wt) mice. (A) Determination of S-Phase cells with 
BrdU (objective 10 × 1). (B) Determination of apoptotic epi-
thelial cells in the tumor by an anti-cleaved caspase-3 anti-
body (objective 20 × 1).
AB
wt
tg
Table 2: Cell membrane expression of β-catenin in adenomas from IGF-II transgenic (tg) and wild-type (wt) mice
preserved reduced loss
genotype weak moderate strong
tg 1 (11.1%) 1 (11.1%) 3 (33.3%) 2 (22.2%) 2 (22.2%)
w t 2  ( 4 0 % )1  ( 2 0 % )1  ( 2 0 % )1  ( 2 0 % )0  ( 0 % )
Preserved: no or < 5% loss of membrane staining; Reduced: weak (loss in about 10–20%); moderate (loss in about 20–50%) and strong (loss in over 
50%); Loss: loss of membrane staining was evident in more than 80%.Journal of Carcinogenesis 2006, 5:24 http://www.carcinogenesis.com/content/5/1/24
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advantage at an early stage that can be eliminated perhaps
due to repair mechanisms. When an ACF at a later stage
progresses towards a tumor, however, IGF-II again pro-
vides a growth advantage as is evidenced by the increased
tumor volumes in IGF-II transgenic mice. Since IGF-II is a
positive regulator for proliferation in colon cancer cells
[15], it is possible that overexpression of IGF-II may lead
to a temporarily higher development of hyperplastic or
atypical crypts, which are well detectable by methylene
blue staining in the early stage of colon cancer develop-
ment, but with a higher potential to regress [6]. That over-
expression of IGF-II in this model acts as a promotor and
not as an initiator of tumor development has to be con-
cluded from similar tumor numbers in IGF-II transgenic
and wild-type mice. This observation is supported by find-
ings in colorectal cancer cell lines, that IGF-II was not able
to stimulate the transformation of cells [15]. A slight but
insignificant increase in colorectal cancer incidence with
increased IGF-II levels, as observed in our study, was also
shown to be present in humans [23,34].
The mitogenic effect of IGF-II is associated with increased 
accumulation of β-catenin in the cytoplasm and nucleus
It is widely accepted that IGFs promote mitogenic effects
[35,36]. In accordance with this, we found that adenomas
in IGF-II transgenic mice have significantly more cells in
the S-phase than adenomas of wild-type mice. The
mitogen-activated protein (MAP) kinase and β-catenin
pathways have been shown to promote proliferation in
different cancer cells when activated [37,38] and several
members of both pathways are known to be hotspots for
genetic alterations commonly found in colon cancer [39-
41]. In tumors MAP kinases can either be activated by IGF-
II via the IGF-1R [42] or via the insulin receptor-A (IR-A)
[35]. As a matter of fact, by immunohistochemical stain-
ing of activated MAP kinase42/44 we found a strong
expression in the aberrant epithelia of colon tumors but
not in normal colon tissue, whereas there was no visible
difference of staining in tumors from IGF-II transgenic
and wild-type animals (data not shown).
Staining for β-catenin revealed an increased accumulation
mainly in the cytoplasm, and to a lower extent in the
nuclei of adenomas from IGF-II transgenic compared to
adenomas from wild-type mice with a concomitant
decline of β-catenin staining at the plasma membrane.
Such stabilized levels of cytoplasmic β-catenin should
pass into the nucleus to increase transcriptional activity
[43,44]. A similar redistribution of β-catenin from the
plasma membrane to the cytoplasm and nucleus was also
found in epithelium to mesenchyme transition (EMT)
[16] that characterizes in embryonic development the
process of conversion of epithelial cells to mesenchymal
cells [45], but is also a characteristic of cancer [46].
Besides the mitogenic actions, IGFs are discussed to be
antiapoptotic [47]. Moreover, antiapoptotic effects have
been shown to be triggered by wnt-1 signaling through
IGFs [48]. Therefore, we evaluated whether IGF-II affects
apoptosis rates in colon tumors as well. In tumors of IGF-
II transgenic and wild-type mice only low rates of apopto-
sis could be detected which is in accordance with the
impaired ability of tumors to control cell mass [49]. How-
ever, IGF-II did not show a significant effect on apoptosis
suggesting that activation of the β-catenin pathway in ade-
nomas of mice has no considerable impact on apoptosis
rates.
Table 3: Cytoplasmic expression of β-catenin in adenomas of IGF-II transgenic (tg) and wild-type (wt) animals
low week moderate strong
genotype + ++ +++ ++++
tg 0 (0%) 1(11.1%) 5 (55.6%) 3 (33.3%)
wt 1 (20%) 2 (40%) 2 (40%) 0 (0%)
Elevation of cytoplasmic staining compared to the internal non-tumor epithelial tissue. low: (+ = non to 5%); week: (++ = 5–15%); moderate: (+++ 
= 15–25%); strong: (++++ = over 25%)
Table 4: Nuclear expression of β-catenin in adenomas of IGF-II transgenic (tg) and wild-type (wt) mice
negative/scattered focal diffuse
genotype + ++ +++
tg 1 (11.1%) 2 (22.2%) 3 (33.3%) 2(22.2%) 1 (11.1%)
wt 2 (40%) 1 (20%) 1 (20%) 1(20%) 0 (0%)
Negative/scattered: no or < 5% scattered positive cells; Focal: positive cells clustered in focal areas (+ = 15–20%; ++ = 20–25%; +++ = 25–30%); 
Diffuse: positive cells distributed diffusely over the whole tumor.Journal of Carcinogenesis 2006, 5:24 http://www.carcinogenesis.com/content/5/1/24
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Activation of the β-catenin-pathway is associated with 
increased IGFBP-2 serum levels in transgenic animals
IGFBP-2 possesses moderately preventing effects on the
development of colorectal cancer [50] most likely by
antagonizing the effect of serum IGF-II [23]. On the other
hand in the case of a manifested colorectal cancer, serum
IGFBP-2 levels are significantly elevated and correlate
with the stage of disease [51]. Since IGFBP2 is a target gene
of the β-catenin/TCF/LEF complex [52] it was not aston-
ishing that we observed significantly higher IGFBP-2
serum levels in IGF-II transgenic mice and a positive cor-
relation between serum IGF-II and IGFBP-2. Given that
the increase of IGF-II in transgenic animals was much
more pronounced than the increase of IGFBP-2 it could be
concluded that IGFBP-2 is not able to block completely
the effects of the transgene.
The higher IGFBP-2 levels in DMH-treated transgenic ani-
mals at the early and late stage of tumor development
were not associated with any effect on tumor incidence. It
has to be stressed here, however, that this is the case under
simultaneously increased IGF-II levels and may be differ-
ent when IGF-II is less increased. That the biological
effects of IGF-II are strictly dependent on IGFBP-2 can be
further derived from the increase of both IGF-II and
IGFBP-2 in wild-type mice with age. In the progressed
stage of tumor development IGFBP-2 seems not to be able
to promote any longer growth inhibiting activities [51]
but enhanced expression might represent an effort to
antagonize the effects of growth factors. In accordance
with this, in our studies one animal showed tremendously
increased IGFBP-2 levels at a later stage that correlated
well with its very poor status because of development of
several large adenomas spreading over the middle and
distal colon.
Lymphangiogenesis in colon tumors is not affected by IGF-
II overexpression
The importance of lymphangiogenesis for the malignant
spread of colorectal tumors has been previously reported
[53]. Moreover, it was described that IGF-II is able to
induce lymphangiogenesis in the mouse cornea in vivo
Immunohistochemical staining of β-catenin in adenomas of DMH-treated animals (objective 40 × 1) Figure 5
Immunohistochemical staining of β-catenin in adenomas of DMH-treated animals (objective 40 × 1). (A) non tumoric colon tis-
sue (a) and normal colon crypts (b) show a strong positive staining for β-catenin in the membrane but not in the cytoplasma or 
in the nucleus. (B) Adenomas with preserved membrane, no nuclear and low cytoplasmic (a) or weak cytoplasmic (b) staining 
of β-catenin. Reduced (weak) membrane, weak cytoplasmic and focal (+) nuclear staining is shown in (c). Reduced (moderate) 
membrane, strong cytoplasmic and focal (++) nuclear staining of β-catenin is given in (d). Loss of membrane staining with 
strong staining of the cytoplasma and focal (+++) nuclear staining of β-catenin is shown in (e) and loss of membrane staining 
with moderate staining of the cytoplasma and diffuse distribution of nuclear staining in the aberrant tissue of the tumor in (f).
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Immunohistochemical staining of lymphatic vessels by the LYVE-1 antibody in normal colon tissue and colon tumors Figure 6
Immunohistochemical staining of lymphatic vessels by the LYVE-1 antibody in normal colon tissue and colon tumors. (A) LYVE-
1 expression was restricted to thin walled lymphatic endothel (L), whereas blood vessels (B) remained unstained in the normal 
colon (a) as well as in tumor tissue (b). Immunohistochemical staining (objective 20 × 1). Lymphatic vessels are scattered along 
the normal colon and penetrate the muscularis mucosae (MM). (B) In pedunculated adenomas Lyve-1 positive vessels (arrows) 
were found in the tumor stalk (S) (a), in the mid (b) and marginal (c) parts of the tumor. Immunohistochemical staining (objec-
tive 10 × 1).
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[22]. In accordance with a study showing LYVE-1, a spe-
cific lymphatic endothelial marker, to be located in the
submucosa of the small intestine [54] we detected LYVE-1
positive endothelia also in the submucosa of the normal
colon. In addition, in adenomas and adenocarcinomas of
the colon we detected LYVE-1 positive lymphatic vessels
reaching the tumor through the stromal stalk and pene-
trating through the connective tissue (lamina propria)
into the tumor, a characteristic not described so far. Nev-
ertheless, there was no effect of IGF-II on lymphangiogen-
esis in tumors investigated.
Summary
In conclusion, IGF-II is a growth promoter during early
and late stages of colorectal cancer development in vivo. It
enhances the growth of initiated cells leading to ACF with
higher crypt multiplicity and also of tumor cells leading to
higher tumor volumes. These effects of IGF-II were associ-
ated with increased cytoplasmic and nuclear accumula-
tion of β-catenin. IGF-II, however, in vivo seems not to be
involved in the transformation process as becomes evi-
dent by the lack of effects on chemically induced number
of tumors.
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